• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Management of hemophagocytic lymphohistiocytosis (HLH) associated with chimeric antigen receptor T-cell (CAR-T) therapy using anti-cytokine therapy: an illustrative case and review of the literature.

作者信息

Major Ajay, Collins Jennifer, Craney Caroline, Heitman Alisa K, Bauer Emily, Zerante Elizabeth, Stock Wendy, Bishop Michael R, Jasielec Jagoda

机构信息

Section of Hematology/Oncology at the University of Chicago, University of Chicago Comprehensive Cancer Center, Chicago, IL, USA.

The David and Etta Jonas Center for Cellular Therapy at the University of Chicago, Chicago, IL, USA.

出版信息

Leuk Lymphoma. 2021 Jul;62(7):1765-1769. doi: 10.1080/10428194.2021.1881507. Epub 2021 Feb 9.

DOI:10.1080/10428194.2021.1881507
PMID:33559517
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8282706/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/71b2/8282706/0a16956d96b0/nihms-1714207-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/71b2/8282706/a13031c14acb/nihms-1714207-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/71b2/8282706/0a16956d96b0/nihms-1714207-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/71b2/8282706/a13031c14acb/nihms-1714207-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/71b2/8282706/0a16956d96b0/nihms-1714207-f0002.jpg

相似文献

1
Management of hemophagocytic lymphohistiocytosis (HLH) associated with chimeric antigen receptor T-cell (CAR-T) therapy using anti-cytokine therapy: an illustrative case and review of the literature.使用抗细胞因子疗法治疗嵌合抗原受体T细胞（CAR-T）疗法相关噬血细胞性淋巴组织细胞增生症（HLH）：1例说明性病例及文献综述
Leuk Lymphoma. 2021 Jul;62(7):1765-1769. doi: 10.1080/10428194.2021.1881507. Epub 2021 Feb 9.
2
A distinct cytokine network distinguishes chimeric antigen receptor T cell (CAR-T)-associated hemophagocytic lymphohistiocytosis-like toxicity (carHLH) from severe cytokine release syndrome following CAR-T therapy.独特的细胞因子网络将嵌合抗原受体 T 细胞（CAR-T）相关噬血细胞性淋巴组织细胞增多症样毒性（carHLH）与 CAR-T 治疗后严重的细胞因子释放综合征区分开来。
Cytotherapy. 2023 Nov;25(11):1167-1175. doi: 10.1016/j.jcyt.2023.06.008. Epub 2023 Jul 21.
3
Low utility of the H-Score and HLH-2004 criteria to identify patients with secondary hemophagocytic lymphohistiocytosis after CAR-T cell therapy for relapsed/refractory diffuse large B-Cell lymphoma.CAR-T 细胞治疗复发/难治性弥漫性大 B 细胞淋巴瘤后，H 评分和 HLH-2004 标准对继发性噬血细胞性淋巴组织细胞增生症患者的识别作用有限。
Leuk Lymphoma. 2022 Jun;63(6):1339-1347. doi: 10.1080/10428194.2021.2024817. Epub 2022 Jan 19.
4
Diagnosis and Management of Secondary HLH/MAS Following HSCT and CAR-T Cell Therapy in Adults; A Review of the Literature and a Survey of Practice Within EBMT Centres on Behalf of the Autoimmune Diseases Working Party (ADWP) and Transplant Complications Working Party (TCWP).成人造血干细胞移植和嵌合抗原受体T细胞疗法后继发性噬血细胞性淋巴组织细胞增生症/巨噬细胞活化综合征的诊断与管理；文献综述及代表自身免疫性疾病工作组（ADWP）和移植并发症工作组（TCWP）对欧洲血液和骨髓移植协会（EBMT）中心的实践调查
Front Immunol. 2020 Mar 31;11:524. doi: 10.3389/fimmu.2020.00524. eCollection 2020.
5
Chimeric antigen receptor T cell therapy and nephrotoxicity: From diagnosis to treatment strategies.嵌合抗原受体 T 细胞疗法与肾毒性：从诊断到治疗策略。
Int Immunopharmacol. 2020 Dec;89(Pt B):107072. doi: 10.1016/j.intimp.2020.107072. Epub 2020 Oct 12.
6
Riding the storm: managing cytokine-related toxicities in CAR-T cell therapy.乘风破浪：CAR-T 细胞疗法中细胞因子相关毒性的管理。
Semin Immunopathol. 2024 Jul 16;46(3-4):5. doi: 10.1007/s00281-024-01013-w.
7
Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome.免疫效应细胞相关性噬血细胞性淋巴组织细胞增生症样综合征。
Transplant Cell Ther. 2023 Jul;29(7):438.e1-438.e16. doi: 10.1016/j.jtct.2023.03.006. Epub 2023 Mar 9.
8
Hemophagocytic lymphohistiocytosis-like toxicity (carHLH) after CD19-specific CAR T-cell therapy.CD19 特异性嵌合抗原受体 T 细胞治疗后噬血细胞性淋巴组织细胞增生症样毒性（carHLH）。
Br J Haematol. 2021 Aug;194(4):701-707. doi: 10.1111/bjh.17662. Epub 2021 Jul 15.
9
Perforin-deficient CAR T cells recapitulate late-onset inflammatory toxicities observed in patients.穿孔素缺陷型 CAR T 细胞重现了患者中观察到的迟发性炎症毒性。
J Clin Invest. 2020 Oct 1;130(10):5425-5443. doi: 10.1172/JCI130059.
10
Chimeric antigen receptor T-cell therapy associated hemophagocytic lymphohistiocytosis syndrome: clinical presentation, outcomes, and management.嵌合抗原受体T细胞疗法相关噬血细胞性淋巴组织细胞增生症综合征：临床表现、结局及管理
Blood Cancer J. 2024 Aug 12;14(1):136. doi: 10.1038/s41408-024-01119-2.

引用本文的文献

1
Chimeric antigen receptor T cell immunotherapy‑associated hemophagocytic lymphohistiocytosis: Pathogenesis, clinical manifestation, diagnosis and management compared with cytokine release syndrome (Review).嵌合抗原受体T细胞免疫疗法相关噬血细胞性淋巴组织细胞增生症：与细胞因子释放综合征相比的发病机制、临床表现、诊断及管理（综述）
Mol Med Rep. 2025 Aug;32(2). doi: 10.3892/mmr.2025.13578. Epub 2025 May 26.
2
Immune Effector Cell-associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS).免疫效应细胞相关噬血细胞性淋巴组织细胞增生症样综合征（IEC-HS）
Hematol Oncol Clin North Am. 2025 Jun;39(3):617-643. doi: 10.1016/j.hoc.2025.02.005. Epub 2025 Mar 29.
3

本文引用的文献

1
Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma.阿那白滞素减轻大B细胞淋巴瘤中CAR T细胞治疗相关毒性的临床疗效。
Blood Adv. 2020 Jul 14;4(13):3123-3127. doi: 10.1182/bloodadvances.2020002328.
2
Myeloma CAR-T CRS Management With IL-1R Antagonist Anakinra.使用白细胞介素-1受体拮抗剂阿那白滞素治疗骨髓瘤嵌合抗原受体T细胞疗法相关的细胞因子释放综合征
Clin Lymphoma Myeloma Leuk. 2020 Sep;20(9):632-636.e1. doi: 10.1016/j.clml.2020.04.020. Epub 2020 May 11.
3
CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial.
In-depth analysis of the safety of CAR-T cell therapy for solid tumors.
嵌合抗原受体T细胞（CAR-T）疗法治疗实体瘤安全性的深入分析。
Front Immunol. 2025 Feb 24;16:1548979. doi: 10.3389/fimmu.2025.1548979. eCollection 2025.
4
Update in Hyperferritinemic Syndromes: Recognition and Management - A Scoping Review.高铁蛋白血症综合征的最新进展：识别与管理——一项范围综述
Brown J Hosp Med. 2022 Aug 19;1(3):37667. doi: 10.56305/001c.37667. eCollection 2022.
5
Invasive Fungal Disease After Chimeric Antigen Receptor-T Immunotherapy in Adult and Pediatric Patients.成人和儿童患者接受嵌合抗原受体T细胞免疫治疗后的侵袭性真菌病
Pathogens. 2025 Feb 8;14(2):170. doi: 10.3390/pathogens14020170.
6
Hemophagocytic lymphohistiocytosis in a patient with Epstein-Barr virus-positive diffuse large B-cell lymphoma treated with chimeric antigen receptor T-cell therapy.一名接受嵌合抗原受体T细胞疗法治疗的爱泼斯坦-巴尔病毒阳性弥漫性大B细胞淋巴瘤患者发生噬血细胞性淋巴组织细胞增生症。
Immunotherapy. 2024;16(18-19):1105-1111. doi: 10.1080/1750743X.2024.2409622. Epub 2024 Oct 17.
7
Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors and CAR-T Cell Therapy: A Comprehensive Imaging-Based Review.免疫检查点抑制剂和CAR-T细胞疗法诱导的免疫相关不良事件：基于影像学的综合综述
Cancers (Basel). 2024 Jul 19;16(14):2585. doi: 10.3390/cancers16142585.
8
The Burden of Invasive Fungal Disease Following Chimeric Antigen Receptor T-Cell Therapy and Strategies for Prevention.嵌合抗原受体T细胞疗法后侵袭性真菌病的负担及预防策略
Open Forum Infect Dis. 2024 Mar 13;11(6):ofae133. doi: 10.1093/ofid/ofae133. eCollection 2024 Jun.
9
Mechanisms and management of CAR T toxicity.嵌合抗原受体T细胞毒性的机制与管理
Front Oncol. 2024 May 21;14:1396490. doi: 10.3389/fonc.2024.1396490. eCollection 2024.
10
CAR-T Cell Therapy in Ovarian Cancer: Where Are We Now?卵巢癌中的嵌合抗原受体T细胞疗法：我们目前的进展如何？
Diagnostics (Basel). 2024 Apr 16;14(8):819. doi: 10.3390/diagnostics14080819.
CD4/CD8 T 细胞选择影响嵌合抗原受体（CAR）T 细胞效力和毒性：一项抗 CD22 CAR T 细胞试验的 I 期更新结果。
J Clin Oncol. 2020 Jun 10;38(17):1938-1950. doi: 10.1200/JCO.19.03279. Epub 2020 Apr 14.
4
Cytokine Release Syndrome: Current Perspectives.细胞因子释放综合征：当前观点
Immunotargets Ther. 2019 Oct 29;8:43-52. doi: 10.2147/ITT.S202015. eCollection 2019.
5
Recommendations for the management of hemophagocytic lymphohistiocytosis in adults.成人噬血细胞性淋巴组织细胞增生症的治疗建议。
Blood. 2019 Jun 6;133(23):2465-2477. doi: 10.1182/blood.2018894618. Epub 2019 Apr 16.
6
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.ASTCT 细胞因子释放综合征和免疫效应细胞相关神经系统毒性的共识分级标准。
Biol Blood Marrow Transplant. 2019 Apr;25(4):625-638. doi: 10.1016/j.bbmt.2018.12.758. Epub 2018 Dec 25.
7
Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells.单核细胞衍生的白细胞介素-1 和白细胞介素-6 对于 CAR T 细胞引起的细胞因子释放综合征和神经毒性是有差异需求的。
Nat Med. 2018 Jun;24(6):739-748. doi: 10.1038/s41591-018-0036-4. Epub 2018 May 28.
8
CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade.嵌合抗原受体 T 细胞引起的细胞因子释放综合征是由巨噬细胞介导的，并可通过白细胞介素-1 阻断来减轻。
Nat Med. 2018 Jun;24(6):731-738. doi: 10.1038/s41591-018-0041-7. Epub 2018 May 28.
9
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.阿基仑赛注射液嵌合抗原受体T细胞疗法治疗难治性大B细胞淋巴瘤
N Engl J Med. 2017 Dec 28;377(26):2531-2544. doi: 10.1056/NEJMoa1707447. Epub 2017 Dec 10.
10
Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.嵌合抗原受体 T 细胞疗法 - 毒性的评估和管理。
Nat Rev Clin Oncol. 2018 Jan;15(1):47-62. doi: 10.1038/nrclinonc.2017.148. Epub 2017 Sep 19.